Literature DB >> 16424278

Use of treatment records and lung lesion scoring to estimate the effect of respiratory disease on growth during early and late finishing periods in South African feedlot cattle.

P N Thompson1, A Stone, W A Schultheiss.   

Abstract

Growth, morbidity, and slaughter data from 2,036 calves in 2 South African feedlots were used to estimate the effect of bovine respiratory disease (BRD) and of lung lesion type and extent on growth during the early (processing to d 35) and late (d 35 to slaughter) finishing periods. Calves were weighed at processing (d 5 after arrival), on d 35, and at slaughter after a mean of 137 d on feed. All calves were monitored twice daily and were treated for BRD if rectal temperature was > 40 degrees C or if other specific signs of BRD were present. After slaughter, the occurrence and extent of parenchymal bronchopneumonic lesions and pleural adhesions were recorded. Subclinical BRD (never treated but with lung lesions at slaughter) occurred in 29.7% and clinical BRD in 22.6% of calves. Lung lesions were present in 43% of calves at slaughter; 8.6% had parenchymal lesions and 38.8% had pleural adhesions. Using a combined case definition (treated for BRD and/or lung lesions present at slaughter), the incidence of BRD was 52.5%. During the early finishing period, clinical BRD reduced ADG by 216 g (P < 0.001), subclinical BRD reduced ADG by 91 g (P < 0.001), and the combined effect of BRD was a 143 g reduction in ADG (P < 0.001). After d 35, animals treated for BRD tended to grow faster than those with subclinical BRD (P = 0.11), indicating that treatment was generally successful in reducing economic losses. The extent of bronchopneumonic lesions at slaughter was not associated with reduced growth during the early finishing period (P = 0.27), but extensive lesions reduced ADG by 88 g during the late period (P = 0.02). In contrast, the extent of pleural adhesions was not associated with reduced growth rate during the late finishing period (P = 0.37) but was strongly associated with reduced ADG before d 35; there was a 101 g reduction (P < 0.001) and a 220 g reduction (P = 0.01) for adhesions involving < 50% and > 50% of the pleural surfaces, respectively. Thus, although the presence of bronchopneumonic lesions and pleural adhesions at slaughter were both associated with reductions in overall ADG, they were indicative of production losses having occurred at different times during the finishing period. The overall effect of BRD was a 24 g reduction in ADG (P = 0.02) and a 5.1 d increase in days on feed (P < 0.001). The hidden cost of reduced growth rate due to BRD amounted to $3.41 per calf with clinical or subclinical BRD, or $1.79 per animal entering the feedlot.

Entities:  

Mesh:

Year:  2006        PMID: 16424278     DOI: 10.2527/2006.842488x

Source DB:  PubMed          Journal:  J Anim Sci        ISSN: 0021-8812            Impact factor:   3.159


  30 in total

1.  Seroprevalence of Anaplasma marginale in 2 Iowa feedlots and its association with morbidity, mortality, production parameters, and carcass traits.

Authors:  Johann F Coetzee; Peggy L Schmidt; Annette M O'Connor; Michael D Apley
Journal:  Can Vet J       Date:  2010-08       Impact factor: 1.008

2.  The use of lung biopsy to determine early lung pathology and its association with health and production outcomes in feedlot steers.

Authors:  Brandy A Burgess; Steve H Hendrick; Colleen M Pollock; Sherry J Hannon; Sameeh M Abutarbush; Amanda Vogstad; G Kee Jim; Calvin W Booker
Journal:  Can J Vet Res       Date:  2013-10       Impact factor: 1.310

3.  An evaluation of the economic effects of bovine respiratory disease on animal performance, carcass traits, and economic outcomes in feedlot cattle defined using four BRD diagnosis methods.

Authors:  Claudia Blakebrough-Hall; Joe P McMeniman; Luciano A González
Journal:  J Anim Sci       Date:  2020-02-01       Impact factor: 3.159

Review 4.  Do antimicrobial mass medications work? A systematic review and meta-analysis of randomised clinical trials investigating antimicrobial prophylaxis or metaphylaxis against naturally occurring bovine respiratory disease.

Authors:  Keith Edward Baptiste; Niels Christian Kyvsgaard
Journal:  Pathog Dis       Date:  2017-09-29       Impact factor: 3.166

Review 5.  The epidemiology of bovine respiratory disease: what is the evidence for preventive measures?

Authors:  Jared D Taylor; Robert W Fulton; Terry W Lehenbauer; Douglas L Step; Anthony W Confer
Journal:  Can Vet J       Date:  2010-12       Impact factor: 1.008

6.  Association between antimicrobial drug class selection for treatment and retreatment of bovine respiratory disease and health, performance, and carcass quality outcomes in feedlot cattle.

Authors:  Johann F Coetzee; Natalia Cernicchiaro; Pritam K Sidhu; Michael D Kleinhenz
Journal:  J Anim Sci       Date:  2020-04-01       Impact factor: 3.159

Review 7.  The epidemiology of bovine respiratory disease: What is the evidence for predisposing factors?

Authors:  Jared D Taylor; Robert W Fulton; Terry W Lehenbauer; Douglas L Step; Anthony W Confer
Journal:  Can Vet J       Date:  2010-10       Impact factor: 1.008

8.  Longitudinal study on morbidity and mortality in white veal calves in Belgium.

Authors:  Bart Pardon; Koen De Bleecker; Miel Hostens; Jozefien Callens; Jeroen Dewulf; Piet Deprez
Journal:  BMC Vet Res       Date:  2012-03-14       Impact factor: 2.741

9.  Differential stress responses among newly received calves: variations in reductant capacity and Hsp gene expression.

Authors:  Harel Eitam; Jacob Vaya; Arieh Brosh; Ala Orlov; Soliman Khatib; Ido Izhaki; Ariel Shabtay
Journal:  Cell Stress Chaperones       Date:  2010-04-18       Impact factor: 3.667

10.  Growth performance and hematological changes of weaned beef calves diagnosed with respiratory disease using respiratory scoring and thoracic ultrasonography.

Authors:  Inmaculada Cuevas-Gómez; Mark McGee; Matthew McCabe; Paul Cormican; Edward O'Riordan; Tara McDaneld; Bernadette Earley
Journal:  J Anim Sci       Date:  2020-11-01       Impact factor: 3.159

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.